In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Degarelix | Natural peptide Oxytocin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 329 | 3,492 (plus 1,148 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 73 (73 in people) | 157 (152 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 148 · 39 active22 more mention it but do not test it | 690 · 65 active238 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Degarelix | Oxytocin |
|---|---|---|
| Adverse eventsWhole body | 5454 | 1261233 |
| Receptor activity and mechanismReproductive and sexual health |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Pitocin says: “Antepartum: medically indicated induction of labor, stimulation or reinforcement of labor, adjunctive therapy in incomplete or inevitable abortion” No central EU authorisation (EMA).
299713
28960801472 |
| Sex hormones and fertilityReproductive and sexual health | 846222 | 150328632 |
|---|
| PharmacokineticsPharmacology | 817 | 9168203 |
|---|
| Sexual functionReproductive and sexual health | 2020 | 7647245 |
|---|
| Tumor growthKidney and urinary | 665781 | 6411 |
|---|
| Heart functionCardiovascular | 33 | 76353110 |
|---|
| Glycemic controlMetabolic and weight | 211 | 312254 |
|---|
| Body weightMetabolic and weight | 422 | 23176 |
|---|
| Inflammation markersCardiovascular | 22 | 3210166 |
|---|
| Cardiovascular eventsCardiovascular | 1275 | 11 |
|---|
| Quality of lifeWhole body | 66 | 22 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Degarelix differs from Gonadorelin at 7 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Degarelix | Oxytocin |
|---|---|---|
| Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | 16% Testosterone recovery 24 weeksn = 1032020 | 14.4% Mean percent change testosterone Dose studied: 24 IUn = 452020 |
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Degarelix | Oxytocin |
|---|---|---|
| Liver fat and liver functionLiverCompared as: difference from placebo, in proportion | No comparable result 1 randomized-trial result measure it in another way or another unit. | −0.01 proportion Difference in liver fat fraction Dose studied: 24 IU four times daily8 weeksn = 61 |
| Sexual functionReproductive and sexual healthCompared as: difference from placebo, in cohen's d | −0.96 Cohen's d Between-group effect size, Sexual Desire Inventory n = 522022 | No comparable result 32 randomized-trial results measure it in another way or another unit. |
|---|
| Quality of lifeMental health and moodCompared as: value in the arm that got the peptide, in % | 85% Quality of life improvement Dose studied: 240/80 mg3 monthsn = 402013 | No comparable result 1 randomized-trial result measure it in another way or another unit. |
|---|
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in mmol/l × min | No comparable result 1 randomized-trial result measure it in another way or another unit. | 2240 mmol/L × min Glucose AUC Placebo: 2190 mmol/L × min Dose studied: 24 IUn = 252024 |
|---|
| Receptor activity and mechanismPharmacologyCompared as: value in the arm that got the peptide, in proteins | No comparable result 1 randomized-trial result measure it in another way or another unit. | 198 proteins Differentially expressed proteins Dose studied: 24 IUsingle dosen = 192026 |
|---|
| Tumor growthCancerCompared as: value in the arm that got the peptide, in % | 52% PSA nadir <0.1 ng/ml response · Degarelix arm, within 6 months after EBRT 18, 24, or 36 monthsn = 3792025 | No randomized trial result 6 results from other study designs. |
|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size | No randomized trial result 8 results from other study designs. | −1.12 effect size Effect size Dose studied: 48 IU/day6 weeksn = 1032020 |
|---|
| Body weightMetabolic and weightCompared as: difference from placebo, in g | No randomized trial result 4 results from other study designs. | 196 g Difference in total fat Dose studied: 24 IU four times daily8 weeksn = 612024 |
|---|
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 88% Adverse event rate 18, 24, or 36 monthsn = 3792025 | No comparable result 66 randomized-trial results measure it in another way or another unit. |
|---|
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in ms | ≤ 10 ms Upper 95% confidence boundary of placebo-corrected ΔΔQTcF · degarelix 2.8 mg, any timepoint Dose studied: 2.8 mg single dosen = 802017 | No comparable result 29 randomized-trial results measure it in another way or another unit. |
|---|
| MortalityInfectionCompared as: value in the arm that got the peptide, in % | 17.7% Inpatient mortality · Degarelix group, 11 patients Placebo group, 6 patients: 17.6% Dose studied: 240 mg oncen = 962022 | No randomized trial result 2 results from other study designs. |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 148 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radiation Therapy Oncology Group1,538 participantsSept 2009 to 4 Sept 2025
Prostate Cancer
Ferring Pharmaceuticals859 participantsJun 2009 to Mar 2011
Prostate Cancer
Ferring Pharmaceuticals620 participantsFeb 2006 to Oct 2007
Prostate Cancer
22 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010
Uterine Atony · Postpartum Hemorrhage
Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020
Dystocia
University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019
Post Partum Hemorrhage
238 more mention it but do not test it. They only measure it or name it in their text.